MX2024003529A - Metodos y composiciones para el tratamiento de la enfermedad renal poliquistica. - Google Patents
Metodos y composiciones para el tratamiento de la enfermedad renal poliquistica.Info
- Publication number
- MX2024003529A MX2024003529A MX2024003529A MX2024003529A MX2024003529A MX 2024003529 A MX2024003529 A MX 2024003529A MX 2024003529 A MX2024003529 A MX 2024003529A MX 2024003529 A MX2024003529 A MX 2024003529A MX 2024003529 A MX2024003529 A MX 2024003529A
- Authority
- MX
- Mexico
- Prior art keywords
- kidney disease
- polycystic kidney
- treatment
- methods
- compositions
- Prior art date
Links
- 208000030761 polycystic kidney disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 abstract 1
- 108091091751 miR-17 stem-loop Proteins 0.000 abstract 1
- 108091069239 miR-17-2 stem-loop Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163253933P | 2021-10-08 | 2021-10-08 | |
| PCT/US2022/077766 WO2023060237A1 (en) | 2021-10-08 | 2022-10-07 | Methods and compositions for treatment of polycystic kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003529A true MX2024003529A (es) | 2024-04-01 |
Family
ID=84246040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003529A MX2024003529A (es) | 2021-10-08 | 2022-10-07 | Metodos y composiciones para el tratamiento de la enfermedad renal poliquistica. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20240294913A1 (https=) |
| EP (1) | EP4413132A1 (https=) |
| JP (1) | JP2024537043A (https=) |
| KR (1) | KR20240073028A (https=) |
| CN (1) | CN118103510A (https=) |
| AR (1) | AR127325A1 (https=) |
| AU (1) | AU2022361062A1 (https=) |
| CA (1) | CA3234547A1 (https=) |
| CL (1) | CL2024000990A1 (https=) |
| CO (1) | CO2024004227A2 (https=) |
| IL (1) | IL311734A (https=) |
| MX (1) | MX2024003529A (https=) |
| TW (1) | TW202320808A (https=) |
| WO (1) | WO2023060237A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023060237A1 (en) | 2021-10-08 | 2023-04-13 | Regulus Therapeutics Inc. | Methods and compositions for treatment of polycystic kidney disease |
| KR20260005213A (ko) * | 2023-04-12 | 2026-01-09 | 레굴루스 테라퓨틱스 인크 | 다낭성 신장 질환 치료를 위한 변형 올리고뉴클레오타이드 |
| EP4680746A1 (en) * | 2023-06-16 | 2026-01-21 | Pyc Therapeutics Limited | Compositions and methods for treatment of kidney disease |
| WO2025193584A1 (en) * | 2024-03-11 | 2025-09-18 | Regulus Therapeutics Inc. | Compound for use in methods for treatment of polycystic kidney disease |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| NZ549535A (en) | 2004-03-17 | 2010-11-26 | Novartis Ag | Use of aliskiren for treating renal and other disorders |
| BRPI0509979A (pt) | 2004-04-20 | 2007-10-16 | Genaco Biomedical Products Inc | método para detectar ncrna |
| EP1791567B1 (en) | 2004-08-10 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| US20070213292A1 (en) * | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| US20070092882A1 (en) * | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
| GB0523659D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| EP2007888A2 (en) | 2006-04-03 | 2008-12-31 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| WO2007126150A1 (ja) | 2006-04-27 | 2007-11-08 | National University Corporation Nagoya University | 癌の新規治療用組成物 |
| US20120283411A9 (en) | 2006-06-29 | 2012-11-08 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CA2927045A1 (en) | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
| WO2008131191A2 (en) | 2007-04-20 | 2008-10-30 | Amgen Inc. | Nucleic acids hybridizable to micro rna and precursors thereof |
| EP2714904B1 (en) | 2007-06-14 | 2017-04-12 | Mirx Therapeutics ApS | Oligonucleotides for modulation of target rna activity |
| EP2623599B1 (en) | 2007-10-04 | 2019-01-02 | Roche Innovation Center Copenhagen A/S | Micromirs |
| US8211867B2 (en) * | 2007-10-29 | 2012-07-03 | Regulus Therapeutics Inc. | Targeting microRNAs for the treatment of liver cancer |
| CA2717792A1 (en) * | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| WO2009143403A1 (en) | 2008-05-23 | 2009-11-26 | Targacept, Inc. | Combination therapy for the management hypertension |
| AU2010319555A1 (en) | 2009-11-11 | 2012-06-14 | Sanford-Burnham Medical Research Institute | Method for generation and regulation of iPS cells and compositions thereof |
| US20130236453A1 (en) | 2012-03-12 | 2013-09-12 | The Ohio State University | Methods and Compositions for Modulating Acute Graft-versus-Host Disease using miR-155 Specific Inhibitors |
| WO2013165320A1 (en) | 2012-05-04 | 2013-11-07 | Agency For Science, Technology And Research | Treating cancer by increasing expression of socs6 |
| SG10201803157XA (en) * | 2013-05-01 | 2018-05-30 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-122 |
| US10660890B2 (en) | 2013-10-24 | 2020-05-26 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) | Treatment of polycystic diseases with an HDAC6 inhibitor |
| JP2017511694A (ja) | 2014-02-12 | 2017-04-27 | トーマス・ジェファーソン・ユニバーシティ | マイクロｒｎａ阻害剤を使用するための組成物および方法 |
| JP6929269B2 (ja) | 2015-08-26 | 2021-09-01 | レグルス セラピューティクス インコーポレイテッド | 多発性嚢胞腎の処置のための方法 |
| WO2018047148A1 (en) | 2016-09-12 | 2018-03-15 | Novartis Ag | Compounds for the inhibition of mirna |
| WO2018106566A1 (en) | 2016-12-05 | 2018-06-14 | Regulus Therapeutics Inc. | Modified oligonucleotides for treatment of polycystic kidney disease |
| AU2017372695B2 (en) | 2016-12-05 | 2023-07-20 | Regulus Therapeutics Inc. | Methods for treatment of polycystic kidney disease |
| US20200392503A1 (en) | 2016-12-05 | 2020-12-17 | Regulus Therapeutics Inc. | Methods and compositions for treatment of polycystic kidney disease |
| US20220380767A1 (en) | 2016-12-05 | 2022-12-01 | Regulus Therapeutics Inc. | Methods and compositions for treatment of polycystic kidney disease |
| EP4098746A4 (en) | 2020-01-31 | 2024-01-24 | National University Corporation Tokai National Higher Education and Research System | SINGLE-STRANDED POLYNUCLEOTIDE |
| WO2023060237A1 (en) | 2021-10-08 | 2023-04-13 | Regulus Therapeutics Inc. | Methods and compositions for treatment of polycystic kidney disease |
| JP2024535445A (ja) | 2021-10-08 | 2024-09-30 | レグルス セラピューティクス インコーポレイテッド | オフターゲット効果を回避するための方法及び組成物 |
| KR20260005213A (ko) | 2023-04-12 | 2026-01-09 | 레굴루스 테라퓨틱스 인크 | 다낭성 신장 질환 치료를 위한 변형 올리고뉴클레오타이드 |
-
2022
- 2022-10-07 WO PCT/US2022/077766 patent/WO2023060237A1/en not_active Ceased
- 2022-10-07 TW TW111138235A patent/TW202320808A/zh unknown
- 2022-10-07 AU AU2022361062A patent/AU2022361062A1/en active Pending
- 2022-10-07 CA CA3234547A patent/CA3234547A1/en active Pending
- 2022-10-07 JP JP2024519270A patent/JP2024537043A/ja active Pending
- 2022-10-07 EP EP22800530.2A patent/EP4413132A1/en active Pending
- 2022-10-07 IL IL311734A patent/IL311734A/en unknown
- 2022-10-07 MX MX2024003529A patent/MX2024003529A/es unknown
- 2022-10-07 KR KR1020247010026A patent/KR20240073028A/ko active Pending
- 2022-10-07 CN CN202280066728.7A patent/CN118103510A/zh active Pending
- 2022-10-11 AR ARP220102755A patent/AR127325A1/es unknown
-
2024
- 2024-03-20 US US18/610,891 patent/US20240294913A1/en active Pending
- 2024-04-03 CL CL2024000990A patent/CL2024000990A1/es unknown
- 2024-04-05 CO CONC2024/0004227A patent/CO2024004227A2/es unknown
-
2025
- 2025-02-12 US US19/052,052 patent/US12559750B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20240294913A1 (en) | 2024-09-05 |
| JP2024537043A (ja) | 2024-10-10 |
| WO2023060237A1 (en) | 2023-04-13 |
| TW202320808A (zh) | 2023-06-01 |
| IL311734A (en) | 2024-05-01 |
| CA3234547A1 (en) | 2023-04-13 |
| KR20240073028A (ko) | 2024-05-24 |
| CL2024000990A1 (es) | 2024-09-27 |
| AU2022361062A1 (en) | 2024-03-21 |
| US20250188466A1 (en) | 2025-06-12 |
| CO2024004227A2 (es) | 2024-04-18 |
| AR127325A1 (es) | 2024-01-10 |
| CN118103510A (zh) | 2024-05-28 |
| US12559750B2 (en) | 2026-02-24 |
| EP4413132A1 (en) | 2024-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024003529A (es) | Metodos y composiciones para el tratamiento de la enfermedad renal poliquistica. | |
| MX2023012981A (es) | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. | |
| MX2022001607A (es) | Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola. | |
| MY183036A (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| PH12020552148A1 (en) | Purinone compounds and their use in treating cancer | |
| EA202091709A1 (ru) | Ингибиторы днк-пк | |
| CR20230057A (es) | Compuestos tríciclicos de urea como inhibidores de jak2 v617f | |
| WO2021243291A3 (en) | Oligonucleotides for sars-cov-2 modulation | |
| MX2022016427A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
| MX379543B (es) | Purinonas como inhibidores de proteasa específica de ubiquitina 1. | |
| EP4635568A3 (en) | Compounds, salts thereof and methods for treatment of diseases | |
| PH12019501224A1 (en) | Compositions for treatment of polycystic kidney disease | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| MX2025011764A (es) | Oligonucleotido modificado para el tratamiento de la enfermedad renal poliquistica | |
| JOP20230250A1 (ar) | تركيبات وطرق لتثبيط إنزيم كيتوهيكسوكيناز (khk) | |
| WO2022031847A3 (en) | Compositions and methods for inhibiting plp1 expression | |
| EP4357334A3 (en) | Conjugated oligonucleotide compounds, methods of making and uses thereof | |
| WO2017035319A8 (en) | Methods for treatment of polycystic kidney disease | |
| MX2024002391A (es) | Inhibidores de indolina de kif18a. | |
| MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| WO2024023262A3 (en) | Nucleic acid compounds | |
| MY202466A (en) | Methods for treatment of polycystic kidney disease | |
| WO2020068950A8 (en) | Hdac1,2 inhibitors | |
| WO2022256631A3 (en) | Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity |